Association of interim PET2 response with outcomes in patients with DLBCL

Using PET to predict failure to salvage therapy in patients with DLBCLПодробнее

LOTIS-2: R/R DLBCL patient characteristics impact DoR to loncastuximab tesirineПодробнее

Low predictive value of PET scans in patients with Hodgkin lymphoma treated with brentuximab vedotinПодробнее

How Can Patients Access the Latest DLBCL Treatment Options?Подробнее

How Is DLBCL Treatment Effectiveness Monitored?Подробнее

DLBCL Prognosis & Management in Front-line Settings #oncology #lungcancer #cancer #2023Подробнее

Using AI to predict the outcomes of patients with R/R DLBCL treated with tisagenlecleucelПодробнее

PET2-assoicated outcomes in patients with DLBCLПодробнее

Results of trial on the use of interim PET scan to identify DLBCLПодробнее

ASH 2014: Phase II trial of interim PET scan-tailored therapy in diffuse large B-cell lymphomaПодробнее

How the treatment of DLBCL and FL are changing in the UKПодробнее

Predictors of long-term survival in patients with DLBCL/HGBCL following autoSCTПодробнее

Do the results of the LYSA LNH 09-1B trial support a PET-adapted treatment strategy for DLBCL?Подробнее

Case study Q&A: Should radiotherapy be used in DLBCL?Подробнее

Interim PET Scans in Diffuse Large B-Cell Lymphoma - More Than Another Biomarker?Подробнее

Interim analysis of anbal-cel for R/R DLBCLПодробнее

PET guided response in lymphoma: the evidence base - Prof Sally BarringtonПодробнее

Should R-CHOP Remain the Standard of Care for DLBCL?Подробнее

Advancements in the DLBCL treatment landscapeПодробнее